New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off t... ( Nexomics Bio...)

New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground

Date:1/21/2009

Nexomics Biosciences Inc., a recently-formed, New Jersey-based biotechnology company, applies cutting edge platform technologies based on large scale protein production, Nuclear Magnetic Resonance (NMR), and X-ray crystallography for use in drug discovery efforts. Nexomics Biosciences has signed a comprehensive license agreement with Rutgers, the State University of New Jersey, that provides Nexomics rights to a portfolio of intellectual property. An additional agreement has been announced with the Center for Advanced Biotechnology and Medicine that provides Nexomics access to laboratory space and equipment.

Highland Park, NJ (PRWEB) January 21, 2009 -- Nexomics Biosciences Inc., a recently-formed, New Jersey-based biotechnology company, applies cutting edge platform technologies based on large scale protein production, Nuclear Magnetic Resonance (NMR), and X-ray crystallography for use in drug discovery efforts. The company provides customers with services in bioinformatics, protein production and structural biology for lead discovery, optimization and development programs. In addition, Nexomics Biosciences will also pursue in-house drug discovery projects on proprietary targets to identify novel small molecule therapeutics.

Nexomics Biosciences has signed a comprehensive license agreement with Rutgers, the State University of New Jersey, that provides Nexomics rights to a portfolio of intellectual property, including a suite of bioinformatics software and an early stage antibiotic screening methodology. In addition, the agreement gives Nexomics rights to use and further develop a novel ribosomal RNA methyltransferase assay for identifying specific binding and inhibition of R1mA proteins from bacterial species. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.

An additional agre
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. New Jersey-Based MedQuist Pays U.S. $6.6 Million to Resolve False Claims Act Allegations
2. Keane Wins $1 Million Electronic Medical Record (EMR) Implementation at New Jersey-Based Acute Care Facility
3. InNexus Biotechnology Completes Preclinical Study Confirming in Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting With FDA
4. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
5. Daniel J. Nevrivy, Ph.D., Biotech and Pharmaceutical Patent Attorney, Launches New Law Firm Aimed at Helping Clients Preserve Their Capital
6. Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results
7. Ezra Van Gelder Joins Microchip Biotechnologies as Executive Vice President R&D
8. Heska to Present at New York Society of Security Analysts 12th Annual Biotech and Specialty Pharma Conference
9. Investor Group Commends Clint Severson for Joining Trinity Biotechs Board of Directors
10. Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of Relapsed Ovarian Cancer
11. Accuray Incorporated Ranked Fifth in Deloittes Technology Fast 50 Program for Silicon Valley Scientific/Medical Equipment, and Biotechnology Companies

Post Your Comments:

New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off t...( Nexomics Bio...),Health